Dramatic Response After Switching MEK Inhibitors in a Patient With Refractory Mixed Histiocytosis [0.03%]
在难治性混合组织细胞增多症患者中更换MEK抑制剂后的戏剧性反应
Anais Roeser,Fanelie Jouenne,Laetitia Vercellino et al.
Anais Roeser et al.
We report the case of a patient with progressive multisystem mixed histiocytosis associating Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) involving the bone marrow, whose lesions harbored the MAP2K1 E102-I103del. Af...
Case Reports
Journal of hematology. 2022 Oct;11(5):185-189. DOI:10.14740/jh1030 2022
Oral Chemotherapy Application in Elderly Patients With Diffuse Large B-Cell Lymphoma: An Alternative Regimen in Retrospective Analysis [0.03%]
老年弥漫大B细胞淋巴瘤患者口服化疗药物的应用：一项回顾性分析中的替代方案
Pi-Han Liao,Ching-Yuan Kuo,Ming-Chun Ma et al.
Pi-Han Liao et al.
Background: A combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is considered the standard treatment for diffuse large B-cell lymphoma (DLBCL). However, no standard treatment ha...
Experiences of a Single Center in One Hundred Ninety-Four Adult Patients With Langerhans Cell Histiocytosis [0.03%]
单中心194例朗格汉斯细胞组织细胞增生症成人患者的临床特征及治疗经验
Claus Doberauer,Christoph Bornemann
Claus Doberauer
Background: Langerhans cell histiocytosis (LCH) is a rare inflammatory myeloid neoplasia belonging to the group of histiocytoses. Inflammatory tissue destruction with fibrosis can result in dysfunction in any organ. Our e...
Marija Malgaj Vrecko,Zeljka Veceric-Haler
Marija Malgaj Vrecko
Coronavirus disease 2019 (COVID-19) has spread tremendously since its first appearance in December 2019. Infected individuals can experience a wide range of systemic complications, including thrombotic microangiopathy (TMA). Like the other ...
Case Reports
Journal of hematology. 2022 Aug;11(4):148-153. DOI:10.14740/jh1019 2022
Durable Remission in Hodgkin Lymphoma Treated With One Cycle of Bleomycin, Vinblastine, Dacarbazine and Two Doses of Nivolumab and Brentuximab Vedotin [0.03%]
培美曲塞，长春氟宁，达卡巴嗪联合两次纳武利尤单抗和贝林妥欧单抗治疗霍奇金淋巴瘤获得持续完全缓解
Binoy Yohannan,Adan Rios,Maximilian Buja
Binoy Yohannan
A 49-year-old woman with systemic lupus erythematosus, lupus nephritis and chronic congestive heart failure presenting with "bulky" cervical lymphadenopathy was diagnosed with classic Hodgkin lymphoma (HL) stage IIIB (positron emission tomo...
Case Reports
Journal of hematology. 2022 Aug;11(4):154-158. DOI:10.14740/jh1035 2022
Adeel Masood,Hamid Ehsan,Qamar Iqbal et al.
Adeel Masood et al.
Light chain deposition disease (LCDD) is a rare hematologic disorder that can affect any organ but predominantly involves the kidneys. Existing literature is limited to case reports and small single-center retrospective series, explaining t...
Immune Checkpoint Inhibitor-Induced Hemophagocytic Lymphohistiocytosis in a Patient With Squamous Cell Carcinoma [0.03%]
免疫检查点抑制剂致淋巴oha综合征1例报告
Rosalyn Marar,Sruti Prathivadhi-Bhayankaram,Mridula Krishnan
Rosalyn Marar
Programmed cell death protein 1 (PD-1) checkpoint inhibitors such as pembrolizumab are novel therapeutics used to treat various advanced malignancies and have been shown to increase patient survival in several studies. However, these drugs ...
Case Reports
Journal of hematology. 2022 Aug;11(4):142-147. DOI:10.14740/jh1033 2022
Hira Akhlaq,Parastou Tizro,Anita Aggarwal et al.
Hira Akhlaq et al.
Conventional Karyotyping and Fluorescence In Situ Hybridization for Detection of Chromosomal Abnormalities in Multiple Myeloma [0.03%]
用于检测多发性骨髓瘤染色体异常的常规核型分析和荧光原位杂交方法
Matthew Crabtree,Jennifer Cai,Xin Qing
Matthew Crabtree
Background: Multiple myeloma (MM) is a genetically heterogeneous disease, with cytogenetic findings that determine disease behavior. Genetic abnormalities can be assessed by fluorescence in situ hybridization (FISH) analy...
Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience [0.03%]
免疫检查点抑制剂贫血的谱系：来自单中心一期临床试验病例系列的经验
Blessie Elizabeth Nelson,Chinenye Lynette Ejezie,Bettzy A Stephen et al.
Blessie Elizabeth Nelson et al.
Immune checkpoint inhibitor anemias (ICI-A) are a rare entity which can be potentially life-threatening without prompt identification. The goal of the study is to characterize the presentation, evaluation, and outcomes of ICI therapy in ear...
Case Reports
Journal of hematology. 2022 Jun;11(3):113-120. DOI:10.14740/jh1006 2022